Retrospective analysis of gefitinib combined with carboplatin plus pemetrexed for NSCLC with activating EGFR mutations

被引：0
|
作者：
Tsurumi, K. [1 ]
Suzuki, A. [1 ]
Watanabe, K. [1 ]
Fukuhara, T. [1 ]
机构：
[1] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.415
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P39-7
引用
收藏
页码：S1378 / S1378
页数：1
相关论文
共 50 条
  • [31] Retrospective Analysis of Antitumor Effects and Biomarkers of Nivolumab in NSCLC Patients with EGFR Mutations
    Watanabe, S.
    Tanaka, H.
    Nozaki, K.
    Sato, M.
    Arita, M.
    Mishina, Y.
    Shoji, S.
    Ichikawa, K.
    Kondo, R.
    Sakagami, T.
    Koya, T.
    Kikuchi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2418 - S2418
  • [32] The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
    Song, Ruiqiang
    Cheng, Yanbo
    Zheng, Tianxi
    CONTRAST MEDIA & MOLECULAR IMAGING, 2022, 2022
  • [33] Randomized Trial of Gefitinib with and without Pemetrexed as First-Line Therapy in East-Asian Patients with Advanced NS NSCLC with EGFR Mutations
    Cheng, Ying
    Murakami, Haruyasu
    Yang, Pan-Chyr
    He, Jianxing
    Nakagawa, Kazuhiko
    Kang, Jin Hyoung
    Kim, Joo-Hang
    Puri, Tarun
    Orlando, Mauro
    Wang, Xin
    Enatsu, Sotaro
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S206 - S206
  • [34] A prospective study to correlate EGFR mutations with gefitinib response in early stage NSCLC
    Rizvi, N
    Pao, W
    Miller, V
    Rusch, V
    Heelan, R
    Ladanyi, M
    Ginex, P
    Tyson, L
    Zakowski, M
    Kris, M
    LUNG CANCER, 2005, 49 : S43 - S43
  • [35] Gefitinib retreatment beyond progression in advanced NSCLC patients with sensitive EGFR mutations
    Sun, L.
    Tu, L.
    Wei, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] Safety of tepotinib plus EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
    Nadal, E.
    Kim, T. M.
    Guarneri, V.
    Voon, P. J.
    Lim, B. K.
    Wislez, M.
    Huang, C.
    Liam, C. K.
    Mazieres, J.
    Tho, L. M.
    Hayashi, H.
    Nguyen, N.
    Chia, P. L.
    De Marinis, F.
    Brutlach, S.
    Adrian, S.
    Ellers-Lenz, B.
    Berghoff, K.
    Karachaliou, N.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [37] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
    Itchins, Malinda
    Liam, Chong Kin
    Ahmad, Azura
    Hsia, Te-Chun
    Zhou, Janying
    Kim, Dong-Wan
    Soo, Ross Andrew
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 82 - 83
  • [38] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
    Liam, Chong Kin
    Ahmad, Azura Rozila
    Hsia, Te-Chun
    Zhou, Jianying
    Kim, Dong-Wan
    Soo, Ross Andrew
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    CANCER RESEARCH, 2022, 82 (12)
  • [39] Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?
    Arulananda, Surein
    John, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : 12 - 14
  • [40] A Phase I Study of Apatinib Combined with Pemetrexed and Carboplatin in Untreated EGFR-Negative Stage IV Non-Squamous NSCLC
    Huang, M.
    Gong, Y.
    Zhu, J.
    Qin, Y.
    Peng, F.
    Ren, L.
    Ding, Z.
    Liu, Y.
    Wang, Y.
    Lu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1072 - S1072
12345